<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="782">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01946243</url>
  </required_header>
  <id_info>
    <org_study_id>18F-AV-45-QP01</org_study_id>
    <nct_id>NCT01946243</nct_id>
  </id_info>
  <brief_title>The Feasibility of Florbetapir Quantitation</brief_title>
  <official_title>The Feasibility and Reliability of Utilizing Commercially Available Quantitative Analysis Software as an Adjunct to the Clinical Qualitative Interpretation of Amyvid Brain Scans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avid Radiopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avid Radiopharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of the study is to assess the feasibility of implementing a
      quantitative process of florbetapir F 18 scan interpretation. The hypothesis is that the use
      of quantitative analysis will increase the accuracy of florbetapir F 18 scan interpretation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Change in Total Accuracy (MIMNeuro Software, Low Accuracy Readers)</measure>
    <time_frame>Scan acquired 50-60 min post-injection</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate whether the addition of quantitation as an adjunct to qualitative interpretations (VisQ) significantly improved the total accuracy of Amyvid scan interpretation in lower accuracy readers. Only the 46 scans with autopsy from A07/A16 are used for this outcome measure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Total Accuracy (Siemens Syngo.PET Software, Experimental Arm Low Accuracy Readers)</measure>
    <time_frame>Scan acquired 50-60 min post-injection</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate whether the addition of quantitation as an adjunct to qualitative interpretations (VisQ) significantly improved the total accuracy of Amyvid scan interpretation in lower accuracy readers. Only the 46 scans with autopsy from A07/A16 are used for this outcome measure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Total Accuracy (MIMNeuro Software, All Readers)</measure>
    <time_frame>Scan acquired 50-60 min post-injection</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate whether the total accuracy of Amyvid VisQ interpretation was non-inferior to the qualitative scan interpretation alone. Only the 46 scans with autopsy from A07/A16 are used for this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Reliability (MIMNeuro Software)</measure>
    <time_frame>Scan acquired 50-60 min post-injection</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate whether VisQ interpretation significantly improved the reliability of Amyvid scan interpretation compared with qualitative scan interpretation alone. The scan interpretation reliability will be evaluated using Fleiss' Kappa statistics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Accuracy (Siemens Syngo.PET Software, Experimental Arm All Readers)</measure>
    <time_frame>Scan acquired 50-60 min post-injection</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate whether the total accuracy of Amyvid VisQ interpretation was non-inferior to the qualitative scan interpretation alone. Only the 46 scans with autopsy from A07/A16 are used for this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Reliability (Siemens Syngo.PET Software)</measure>
    <time_frame>Scan acquired 50-60 min post-injection</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate whether VisQ interpretation significantly improved the reliability of Amyvid scan interpretation compared with qualitative scan interpretations alone. The scan interpretation reliability will be evaluated using Fleiss' Kappa statistics.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Alzheimers Disease</condition>
  <arm_group>
    <arm_group_label>Physician Readers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Physician readers will interpret Amyvid scans using qualitative analysis followed by the use of quantitation. No subjects will be exposed to Florbetapir F 18 as part of this study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Florbetapir F18</intervention_name>
    <description>No Florbetapir F 18 will be administered in this study.</description>
    <arm_group_label>Physician Readers</arm_group_label>
    <other_name>Amyvid</other_name>
    <other_name>18F-AV-45</other_name>
    <other_name>florbetapir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Readers have undergone Amyvid reader training

          -  Readers have minimal experience with quantitation of amyloid PET scans

        Exclusion Criteria:

          -  Readers have previously been trained to quantitate amyloid PET scans
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Medical Officer</last_name>
    <role>Study Director</role>
    <affiliation>Avid Radiopharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <lastchanged_date>June 1, 2015</lastchanged_date>
  <firstreceived_date>September 17, 2013</firstreceived_date>
  <firstreceived_results_date>April 27, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Florbetapir PET Scans</title>
          <description>No subjects were enrolled in this study. Readers interpreted 96 Florbetapir scans from subjects enrolled in previous studies (A07[NCT00857415]/A16[NCT01447719] and A17[NCT01400425]). Scans used in the study included 46 scans with autopsy (A07/A16) and 50 randomly selected non-autopsy scans (A17).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Florbetapir PET Scans</title>
          <description>No subjects were enrolled in this study. Readers interpreted 96 Florbetapir scans from subjects enrolled in previous studies (A07[NCT00857415]/A16[NCT01447719] and A17[NCT01400425]). Scans used in the study included 46 scans with autopsy (A07/A16) and 50 randomly selected non-autopsy scans (A17).</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="96"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="76.9" spread="10.23"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="48"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="48"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Not Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="92"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="89"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Other</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="96"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Total Accuracy (MIMNeuro Software, Low Accuracy Readers)</title>
        <description>Evaluate whether the addition of quantitation as an adjunct to qualitative interpretations (VisQ) significantly improved the total accuracy of Amyvid scan interpretation in lower accuracy readers. Only the 46 scans with autopsy from A07/A16 are used for this outcome measure.</description>
        <time_frame>Scan acquired 50-60 min post-injection</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Qualitative</title>
            <description>Qualitative scan interpretation only</description>
          </group>
          <group group_id="O2">
            <title>VisQ</title>
            <description>Quantitation as an adjunct to qualitative scan interpretation</description>
          </group>
          <group group_id="O3">
            <title>Change</title>
            <description>Change = VisQ - Qualitative</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                  <measurement group_id="O2" value="46"/>
                  <measurement group_id="O3" value="46"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Total Accuracy (MIMNeuro Software, Low Accuracy Readers)</title>
            <description>Evaluate whether the addition of quantitation as an adjunct to qualitative interpretations (VisQ) significantly improved the total accuracy of Amyvid scan interpretation in lower accuracy readers. Only the 46 scans with autopsy from A07/A16 are used for this outcome measure.</description>
            <units>Percent Accuracy</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="81.7" spread="2.4"/>
                  <measurement group_id="O2" value="88.8" spread="3.1"/>
                  <measurement group_id="O3" value="7.1" spread="1.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Paired t-test to test whether the change is equal to zero or not.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0029</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Accuracy (MIMNeuro Software, All Readers)</title>
        <description>Evaluate whether the total accuracy of Amyvid VisQ interpretation was non-inferior to the qualitative scan interpretation alone. Only the 46 scans with autopsy from A07/A16 are used for this outcome measure.</description>
        <time_frame>Scan acquired 50-60 min post-injection</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Qualitative</title>
            <description>Qualitative scan interpretation only</description>
          </group>
          <group group_id="O2">
            <title>VisQ</title>
            <description>Quantitation as an adjunct to qualitative scan interpretation</description>
          </group>
          <group group_id="O3">
            <title>Change</title>
            <description>Change = VisQ - Qualitative</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                  <measurement group_id="O2" value="46"/>
                  <measurement group_id="O3" value="46"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Total Accuracy (MIMNeuro Software, All Readers)</title>
            <description>Evaluate whether the total accuracy of Amyvid VisQ interpretation was non-inferior to the qualitative scan interpretation alone. Only the 46 scans with autopsy from A07/A16 are used for this outcome measure.</description>
            <units>Percent Accuracy</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="89.5" spread="1.4"/>
                  <measurement group_id="O2" value="93.8" spread="1.2"/>
                  <measurement group_id="O3" value="4.2" spread="0.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>Non-inferiority demonstrated if the lower bound of the one-sided 97.5% confidence interval is greater than -3%.</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>4.2</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>2.7</ci_lower_limit>
            <estimate_desc>Units: Percent Accuracy</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Reliability (MIMNeuro Software)</title>
        <description>Evaluate whether VisQ interpretation significantly improved the reliability of Amyvid scan interpretation compared with qualitative scan interpretation alone. The scan interpretation reliability will be evaluated using Fleiss' Kappa statistics.</description>
        <time_frame>Scan acquired 50-60 min post-injection</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Qualitative</title>
            <description>Qualitative scan interpretation only</description>
          </group>
          <group group_id="O2">
            <title>VisQ</title>
            <description>Quantitation as an adjunct to qualitative scan interpretation</description>
          </group>
          <group group_id="O3">
            <title>Change</title>
            <description>Change = VisQ - Qualitative</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="96"/>
                  <measurement group_id="O2" value="96"/>
                  <measurement group_id="O3" value="96"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Reliability (MIMNeuro Software)</title>
            <description>Evaluate whether VisQ interpretation significantly improved the reliability of Amyvid scan interpretation compared with qualitative scan interpretation alone. The scan interpretation reliability will be evaluated using Fleiss' Kappa statistics.</description>
            <units>Fleiss Kappa</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>All study cases</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.72" lower_limit="0.710" upper_limit="0.737"/>
                  <measurement group_id="O2" value="0.79" lower_limit="0.774" upper_limit="0.801"/>
                  <measurement group_id="O3" value="0.06" lower_limit="0.018" upper_limit="0.112"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Autopsy cases</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.73" lower_limit="0.709" upper_limit="0.747"/>
                  <measurement group_id="O2" value="0.81" lower_limit="0.787" upper_limit="0.825"/>
                  <measurement group_id="O3" value="0.08" lower_limit="0.005" upper_limit="0.151"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Non-autopsy cases</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.72" lower_limit="0.700" upper_limit="0.737"/>
                  <measurement group_id="O2" value="0.77" lower_limit="0.752" upper_limit="0.789"/>
                  <measurement group_id="O3" value="0.05" lower_limit="-0.013" upper_limit="0.113"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Superiority demonstrated if lower bound of two-sided 95% confidence interval (CI) greater than 0, for the change in kappa statistic.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>lower bound of two-sided 95% CI</param_type>
            <param_value>0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.018</ci_lower_limit>
            <ci_upper_limit>0.112</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Accuracy (Siemens Syngo.PET Software, Experimental Arm All Readers)</title>
        <description>Evaluate whether the total accuracy of Amyvid VisQ interpretation was non-inferior to the qualitative scan interpretation alone. Only the 46 scans with autopsy from A07/A16 are used for this outcome measure.</description>
        <time_frame>Scan acquired 50-60 min post-injection</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Qualitative</title>
            <description>Qualitative scan interpretation only</description>
          </group>
          <group group_id="O2">
            <title>VisQ</title>
            <description>Quantitation as an adjunct to qualitative scan interpretation</description>
          </group>
          <group group_id="O3">
            <title>Change</title>
            <description>Change = VisQ - Qualitative</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                  <measurement group_id="O2" value="46"/>
                  <measurement group_id="O3" value="46"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Total Accuracy (Siemens Syngo.PET Software, Experimental Arm All Readers)</title>
            <description>Evaluate whether the total accuracy of Amyvid VisQ interpretation was non-inferior to the qualitative scan interpretation alone. Only the 46 scans with autopsy from A07/A16 are used for this outcome measure.</description>
            <units>Percent Accuracy</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="91.6" spread="0.8"/>
                  <measurement group_id="O2" value="93.9" spread="0.7"/>
                  <measurement group_id="O3" value="2.3" spread="0.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>Non-inferiority demonstrated if the lower bound of the one-sided 97.5% confidence interval is greater than -3%.</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.3</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>0.8</ci_lower_limit>
            <estimate_desc>Units: Percent Accuracy</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Reliability (Siemens Syngo.PET Software)</title>
        <description>Evaluate whether VisQ interpretation significantly improved the reliability of Amyvid scan interpretation compared with qualitative scan interpretations alone. The scan interpretation reliability will be evaluated using Fleiss' Kappa statistics.</description>
        <time_frame>Scan acquired 50-60 min post-injection</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Qualitative</title>
            <description>Qualitative scan interpretation only</description>
          </group>
          <group group_id="O2">
            <title>VisQ</title>
            <description>Quantitation as an adjunct to qualitative scan interpretation</description>
          </group>
          <group group_id="O3">
            <title>Change</title>
            <description>Change = VisQ - Qualitative</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="96"/>
                  <measurement group_id="O2" value="96"/>
                  <measurement group_id="O3" value="96"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Reliability (Siemens Syngo.PET Software)</title>
            <description>Evaluate whether VisQ interpretation significantly improved the reliability of Amyvid scan interpretation compared with qualitative scan interpretations alone. The scan interpretation reliability will be evaluated using Fleiss' Kappa statistics.</description>
            <units>Fleiss Kappa</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>All study cases</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.75" lower_limit="0.738" upper_limit="0.761"/>
                  <measurement group_id="O2" value="0.82" lower_limit="0.805" upper_limit="0.827"/>
                  <measurement group_id="O3" value="0.07" lower_limit="0.007" upper_limit="0.125"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Autopsy cases</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.76" lower_limit="0.749" upper_limit="0.781"/>
                  <measurement group_id="O2" value="0.80" lower_limit="0.785" upper_limit="0.817"/>
                  <measurement group_id="O3" value="0.04" lower_limit="-0.046" upper_limit="0.112"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Non-autopsy cases</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.73" lower_limit="0.718" upper_limit="0.749"/>
                  <measurement group_id="O2" value="0.83" lower_limit="0.815" upper_limit="0.846"/>
                  <measurement group_id="O3" value="0.10" lower_limit="0.008" upper_limit="0.187"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Superiority demonstrated if lower bound of two-sided 95% CI greater than 0, for the change in kappa statistic.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0280</p_value>
            <method>Monte Carlo test</method>
            <param_type>lower bound of two-sided 95% CI</param_type>
            <param_value>0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.007</ci_lower_limit>
            <ci_upper_limit>0.125</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Total Accuracy (Siemens Syngo.PET Software, Experimental Arm Low Accuracy Readers)</title>
        <description>Evaluate whether the addition of quantitation as an adjunct to qualitative interpretations (VisQ) significantly improved the total accuracy of Amyvid scan interpretation in lower accuracy readers. Only the 46 scans with autopsy from A07/A16 are used for this outcome measure.</description>
        <time_frame>Scan acquired 50-60 min post-injection</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Qualitative</title>
            <description>Qualitative scan interpretation only</description>
          </group>
          <group group_id="O2">
            <title>VisQ</title>
            <description>Quantitation as an adjunct to qualitative scan interpretation</description>
          </group>
          <group group_id="O3">
            <title>Change</title>
            <description>Change = VisQ - Qualitative</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                  <measurement group_id="O2" value="46"/>
                  <measurement group_id="O3" value="46"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Total Accuracy (Siemens Syngo.PET Software, Experimental Arm Low Accuracy Readers)</title>
            <description>Evaluate whether the addition of quantitation as an adjunct to qualitative interpretations (VisQ) significantly improved the total accuracy of Amyvid scan interpretation in lower accuracy readers. Only the 46 scans with autopsy from A07/A16 are used for this outcome measure.</description>
            <units>Percent Accuracy</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="87.0" spread="1.0"/>
                  <measurement group_id="O2" value="91.8" spread="1.1"/>
                  <measurement group_id="O3" value="4.9" spread="1.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Paired t-test to test whether the change is equal to zero or not.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0025</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>No subjects received florbetapir in this study. This study consisted of re-reads of scans previously acquired in other clinical studies (A07, A16, and A17).</desc>
      <group_list>
        <group group_id="E1">
          <title>Florbetapir PET Scans</title>
          <description>No subjects received florbetapir in this study. This study consisted of re-reads of scans previously acquired in other clinical studies (A07/A16 and A17).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No conclusions can be drawn regarding the relative performance of software packages (different readers) or on impact of additional qualitative practice on quantitative interpretation results (Vis Q always after Qualitative).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Avid Radiopharmaceuticals</organization>
      <phone>215-298-0700</phone>
      <email>clinicaloperations@avidrp.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
